Joseph B Domachowske
Overview
Explore the profile of Joseph B Domachowske including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
121
Citations
2719
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Suryadevara M, Wang D, Fajardo F, Aponte J, Heras F, Aponte C, et al.
Int J Environ Res Public Health
. 2025 Feb;
22(2).
PMID: 40003497
Implementation of RSV prevention strategies requires an understanding of seasonal virus epidemiology; yet, such data are lacking in many tropical regions. We describe the seasonality and environmental factors associated with...
2.
Nolan T, Bhusal C, Hoberman A, Llapur C, Voloshyna O, Fink E, et al.
Clin Infect Dis
. 2024 Dec;
PMID: 39722560
Background: A MenABCWY vaccine containing 4CMenB and MenACWY-CRM vaccine components has been developed to protect against the five meningococcal serogroups that cause most invasive disease cases. Methods: In this phase...
3.
Tuffy K, Ahani B, Domachowske J, Furuno K, Ji H, Madhi S, et al.
Vaccine
. 2024 Sep;
42(24):126276.
PMID: 39241352
Background: Nirsevimab is an extended half-life monoclonal antibody (mAb) licensed for the prevention of respiratory syncytial virus (RSV)-associated lower respiratory tract disease in neonates, infants and medically vulnerable children. We...
4.
Domachowske J
J Pediatric Infect Dis Soc
. 2024 Jul;
13(Supplement_2):S93-S102.
PMID: 38995086
The United States (U.S.) Food and Drug Administration (FDA) oversees the safety and quality of drugs and vaccines that are used in the U.S. Administration of the FDA falls under...
5.
Domachowske J
J Pediatric Infect Dis Soc
. 2024 Jul;
13(Supplement_2):S91-S92.
PMID: 38995084
No abstract available.
6.
Madhi S, Ceballos A, Cousin L, Domachowske J, Langley J, Lu E, et al.
Pediatr Infect Dis J
. 2024 Jul;
PMID: 38985986
Background: There is limited evidence regarding the proportion of wheeze in young children attributable to respiratory syncytial virus lower respiratory tract infections (RSV-LRTI) occurring early in life. This cohort study...
7.
Ahani B, Tuffy K, Aksyuk A, Wilkins D, Abram M, Dagan R, et al.
Nat Commun
. 2024 Apr;
15(1):3026.
PMID: 38589384
No abstract available.
8.
Domachowske J
J Pediatric Infect Dis Soc
. 2024 Mar;
13(Supplement_2):S115-S124.
PMID: 38554101
To date, safe and effective strategies to prevent medically attended respiratory syncytial virus (RSV) illness across the infant population have been limited to passive immunoprophylaxis for those at highest risk....
9.
Daniels D, Wang D, Suryadevara M, Wolf Z, Nelson C, Suh M, et al.
Pediatr Infect Dis J
. 2023 Sep;
42(12):1056-1062.
PMID: 37725814
Background: Respiratory syncytial virus (RSV) bronchiolitis is the leading cause of hospitalizations among infants in the United States. Unpredictability in RSV seasonality has occurred following the onset of the coronavirus...
10.
Ahani B, Tuffy K, Aksyuk A, Wilkins D, Abram M, Dagan R, et al.
Nat Commun
. 2023 Jul;
14(1):4347.
PMID: 37468530
Nirsevimab is a monoclonal antibody that binds to the respiratory syncytial virus (RSV) fusion protein. During the Phase 2b (NCT02878330) and MELODY (NCT03979313) clinical trials, infants received one dose of...